Trial Profile

Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TLL 018 (Primary)
Indications Chronic urticaria
Focus Adverse reactions; Pharmacokinetics
Sponsors Hangzhou Highlightll Pharmaceutical

Most Recent Events

29 Feb 2024 Status changed from active, no longer recruiting to completed.
26 Feb 2024 Results assessing the efficacy and safety of TLL-018 in chronic spontaneous urticaria (CSU) adults with inadequate response to antihistamine presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
30 Oct 2023 Planned End Date changed from 30 Sep 2023 to 30 Nov 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com